Aethlon Medical, Inc. is a medical therapeutic company which develop the Hemopurifier, an immunotherapeutic device aimed at treating cancer, life-threatening viral infections, and aiding in organ transplantation. Pre-clinical studies show it can remove harmful exosomes from biological fluids using lectin-based technology. The FDA has designated it as a Breakthrough Device for advanced or metastatic cancer unresponsive to standard therapies and for treating life-threatening viruses not addressed by approved therapies, with an open Investigational Device Exemption. We show 46 historical shares outstanding datapoints in our AEMD shares outstanding history coverage, used to compute AEMD market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AEMD market cap history over the course of time is important for investors
interested in comparing AEMD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AEMD versus a peer is one thing; comparing
AEMD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AEMD can fluctuate over the course of history.
With this page we aim to empower investors researching AEMD by allowing them to research the AEMD market cap history. |
Free AEMD Email Alerts:
Video: The Importance of Market Cap
